The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Preferential induction of apoptosis for primary human leukemic stem cells
Open accessAbstract
Acute myelogenous leukemia (AML) is typically a disease of stem/progenitor cell origin. Interestingly, the leukemic stem cell (LSC) shares many characteristics with normal hematopoietic stem cells (HSCs) including the ability to self-renew and a predominantly G 0 cell-cycle status. Thus, although conventional chemotherapy regimens often ablate actively cycling leukemic blast cells, the primitive LSC population is likely to be drug-resistant. Moreover, given the quiescent nature of LSCs, current drugs may not effectively distinguish between malignant stem cells and normal HSCs. Nonetheless, based on recent studies of LSC molecular biology, we hypothesized that certain unique properties of leukemic cells could be exploited to induce apoptosis in the LSC population while sparing normal stem cells. In this report we describe a strategy using treatment of primary AML cells with the proteasome inhibitor carbobenzoxyl- l -leucyl- l -leucyl- l -leucinal (MG-132) and the anthracycline idarubicin. Comparison of normal and leukemic specimens using in vitro culture and in vivo xenotransplantation assays shows that the combination of these two agents induces rapid and extensive apoptosis of the LSC population while leaving normal HSCs viable. Molecular genetic studies using a dominant-negative allele of inhibitor of nuclear factor κB (IκBα) demonstrate that inhibition of nuclear factor κB (NF-κB) contributes to apoptosis induction. In addition, gene-expression analyses suggest that activation of p53-regulated genes are also involved in LSC apoptosis. Collectively, these findings demonstrate that malignant stem cells can be preferentially targeted for ablation. Further, the data begin to elucidate the molecular mechanisms that underlie LSC-specific apoptosis and suggest new directions for AML therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
NF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z.-W. (2002) · Nature Reviews Cancer · doi:10.1038/nrc780 · Cited by 2,478
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469
Lowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
Jordan, C., Upchurch, D., Szilvassy, S., Guzman, M., Howard, D., Pettigrew, A., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401903 · Cited by 821
Self-citationNuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells
Guzman, M. L., Neering, S. J., Upchurch, D., Grimes, B., Howard, D. S., Rizzieri, D. A., Luger, S. M., & Jordan, C. T. (2001) · Blood · doi:10.1182/blood.v98.8.2301 · Cited by 758
Self-citationManipulation of Adenovirus Vectors
Graham, F. L., & Prevec, L. (2003) · Gene Transfer and Expression Protocols · doi:10.1385/0-89603-178-0:109 · Cited by 752
Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Müller, C., Grüning, W., Kratz-Albers, K., Serve, S., Steur, C., et al. (2000) · Blood · doi:10.1182/blood.v96.12.3907 · Cited by 606
The proteasome: a novel target for cancer chemotherapy
Almond, J., & Cohen, G. (2002) · Leukemia · doi:10.1038/sj.leu.2402417 · Cited by 538
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
Levis, M., Allebach, J., Tse, K.-F., Zheng, R., Baldwin, B. R., Smith, B. D., Jones-Bolin, S., Ruggeri, B., Dionne, C., & Small, D. (2002) · Blood · doi:10.1182/blood.v99.11.3885 · Cited by 475
p53-dependent Induction of Apoptosis by Proteasome Inhibitors
Lopes, U. G., Erhardt, P., Yao, R., & Cooper, G. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.20.12893 · Cited by 467
Nuclear transcription factor-κB as a target for cancer drug development
Garg, A., & Aggarwal, B. (2002) · Leukemia · doi:10.1038/sj.leu.2402482 · Cited by 441
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
Stirewalt, D. L., Kopecky, K. J., Meshinchi, S., Appelbaum, F. R., Slovak, M. L., Willman, C. L., & Radich, J. P. (2001) · Blood · doi:10.1182/blood.v97.11.3589 · Cited by 431
Blair, A., Hogge, D. E., Ailles, L. E., Lansdorp, P. M., & Sutherland, H. J. (1997) · Blood · doi:10.1182/blood.v89.9.3104 · Cited by 335
The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance
Mayo, M. W., & Baldwin, A. S. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(00)00002-0 · Cited by 324
p53 stabilization is decreased upon NFκB activation
Tergaonkar, V., Pando, M., Vafa, O., Wahl, G., & Verma, I. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00068-5 · Cited by 313
Fialkow, P. J., Singer, J. W., Raskind, W. H., Adamson, J. W., Jacobson, R. J., Bernstein, I. D., Dow, L. W., Najfeld, V., & Veith, R. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708203170802 · Cited by 306
Acute nonlymphocytic leukemia: heterogeneity of stem cell origin
Fialkow, P., Singer, J., Adamson, J., Vaidya, K., Dow, L., Ochs, J., & Moohr, J. (1981) · Blood · doi:10.1182/blood.v57.6.1068.1068 · Cited by 273
Blair, A., Hogge, D. E., & Sutherland, H. J. (1998) · Blood · doi:10.1182/blood.v92.11.4325 · Cited by 236
Lansdorp, P. M., & Dragowska, W. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.6.1501 · Cited by 216
Gilliland, D. G., & Griffin, J. D. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00003 · Cited by 202
Levis, M., Tse, K.-F., Smith, B. D., Garrett, E., & Small, D. (2001) · Blood · doi:10.1182/blood.v98.3.885 · Cited by 189
Signaling pathways activated by daunorubicin
Laurent, G., & Jaffrézou, J.-P. (2001) · Blood · doi:10.1182/blood.v98.4.913 · Cited by 187
Assay of human stem cells by repopulation of NOD/SCID mice
Dick, J. E., Bhatia, M., Gan, O., Kapp, U., & Wang, J. C. Y. (1997) · Stem Cells · doi:10.1002/stem.5530150826 · Cited by 180
Blair, A., & Sutherland, H. J. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(00)00155-7 · Cited by 165
Normal and leukemic human stem cells assayed in SCID mice
Dick, J. E. (1996) · Seminars in Immunology · doi:10.1006/smim.1996.0025 · Cited by 154
Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer
Adams, J. (2002) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(02)00343-5 · Cited by 150
Characterization of a hierarchy in human acute myeloid leukemia progenitor cells
Sutherland, H., Blair, A., & Zapf, R. (1996) · Blood · doi:10.1182/blood.v87.11.4754.bloodjournal87114754 · Cited by 139
Unique molecular and cellular features of acute myelogenous leukemia stem cells
Jordan, C. T. (2002) · Leukemia · doi:10.1038/sj.leu.2402446 · Cited by 129
Self-citationJordan, C. T., Yamasaki, G., & Minamoto, D. (1996) · PubMed · Cited by 125
Self-citationBoland, M. P., Foster, S. J., & O'Neill, L. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.20.12952 · Cited by 122
Terpstra, W. E., Ploemacher, R., Prins, A., van Lom, K., Pouwels, K., Wognum, A., Wagemaker, G., Löwenberg, B., & Wielenga, J. (1996) · Blood · doi:10.1182/blood.v88.6.1944.bloodjournal8861944 · Cited by 108
Ailles, L., Gerhard, B., & Hogge, D. E. (1997) · Blood · doi:10.1182/blood.v90.7.2555 · Cited by 99
Naujokat, C., Sezer, O., Zinke, H., Leclere, A., Hauptmann, S., & Possinger, K. (2000) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2000.065004221.x · Cited by 89
Dietrich, C., Bartsch, T., Schanz, F., Oesch, F., & Wieser, R. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10815 · Cited by 77
Lapidot, T., Fajerman, Y., & Kollet, Ó. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050150 · Cited by 76
Guzman, M. L., Upchurch, D., Grimes, B., Howard, D. S., Rizzieri, D. A., Luger, S. M., Phillips, G. L., & Jordan, C. T. (2001) · Blood · doi:10.1182/blood.v97.7.2177 · Cited by 45
Self-citationThe proteasome: a molecular target for cancer therapy
Hallahan, D. E., & Teng, M. F. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00517-4 · Cited by 6
Cited by
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Phenotypic characterization of human colorectal cancer stem cells
Dalerba, P., Dylla, S. J., Park, I.-K., Liu, R., Wang, X., Cho, R. W., Hoey, T., Gurney, A., Huang, E. H., Simeone, D. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703478104 · Cited by 2,184
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment
Vermeulen, L., De Sousa E Melo, F., van der Heijden, M., Cameron, K., de Jong, J. H., Borovski, T., Tuynman, J. B., Todaro, M., Merz, C., Rodermond, H., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2048 · Cited by 1,804
Jordan, C. T., Guzman, M. L., & Noble, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra061808 · Cited by 1,702
Self-citationApplying the principles of stem-cell biology to cancer
Pardal, R., Clarke, M. F., & Morrison, S. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1232 · Cited by 1,624
Metadata
- Authors
- Guzman, M. L., Swiderski, C. F., Howard, D. S., Grimes, B. A., Rossi, R. M., Szilvassy, S. J., & Jordan, C. T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2002-11-25
- Volume
- 99
- Issue
- 25
- Pages
- 16220-16225
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2074725580
- Cited by
- 426
- References
- 45
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.